One or two intact local summaries. No averaged regimen, patient-specific dose or automatic source preference.
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The live source uses the spelling Amantidine in its heading and URL; amantadine is retained as the searchable ingredient name. This is not a modified-release amantadine protocol.
The retrieved SYMMETREL mirror uses 100 mg every 7 days below 15, while the US IR capsule label uses 200 mg every 7 days. Other interval bands and first-dose instructions also differ; mirror jurisdiction/applicability is unreconciled.
What to reconcile: Treat the SYMMETREL mirror as a source-quality hold. Do not apply its schedule to the US IR capsule or an extended-release product.
Open this note and its source referencesFor the US immediate-release product use its applicable official label; do not blend the conflicting mirror interval or extend the table to ER products.
Renal accumulation has caused fatal toxicity when doses exceeded recommendations. Hemodialysis removes negligible amounts.
Monitor CNS effects, edema and orthostatic hypotension. Do not abruptly discontinue in Parkinson disease. Historical influenza indications are not a current antiviral recommendation.
| Indexed CrCl (mL/min/1.73 m2) | Source-specific instruction |
|---|---|
| 30-50 | 200 mg on day 1, then 100 mg daily |
| 15-29 | 200 mg on day 1, then 100 mg on alternate days |
| <15 | 200 mg every 7 days |
| Setting | Source-specific instruction |
|---|---|
| Hemodialysis | 200 mg every 7 days |
Amantadine immediate-release - US label renal table
| Indexed CrCl (mL/min/1.73 m2) | Source-specific instruction |
|---|---|
| 30-50 | 200 mg on day 1, then 100 mg daily |
| 15-29 | 200 mg on day 1, then 100 mg on alternate days |
| <15 | 200 mg every 7 days |
Amantadine immediate-release - US label HD
| Setting | Source-specific instruction |
|---|---|
| Hemodialysis | 200 mg every 7 days |
Renal accumulation has caused fatal toxicity when doses exceeded recommendations. Hemodialysis removes negligible amounts.
Monitor CNS effects, edema and orthostatic hypotension. Do not abruptly discontinue in Parkinson disease. Historical influenza indications are not a current antiviral recommendation.
RDM64-official-amantidine-b8a48f2047-C1 · Source locator: Dosage for Impaired Renal Function; warnings; renal PK.
Renal accumulation has caused fatal toxicity when doses exceeded recommendations. Hemodialysis removes negligible amounts.
Monitor CNS effects, edema and orthostatic hypotension. Do not abruptly discontinue in Parkinson disease. Historical influenza indications are not a current antiviral recommendation.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
Pinned reference: https://globalrph.com/blogCalcs/renal-dosing-master/compare.php?id=amantidine&s1=RDM64-official-amantidine-b8a48f2047&h1=c0d0d13bc5ad724c329d2d2ad2c0209fcf7973c47f4c545af8e85694d7e68a0e